0001213900-21-017861.txt : 20210326
0001213900-21-017861.hdr.sgml : 20210326
20210326060158
ACCESSION NUMBER: 0001213900-21-017861
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20210326
DATE AS OF CHANGE: 20210326
EFFECTIVENESS DATE: 20210326
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADIAL PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001513525
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 800667150
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-393625
FILM NUMBER: 21774551
BUSINESS ADDRESS:
STREET 1: 1180 SEMINOLE TRAIL
STREET 2: SUITE 495
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22901
BUSINESS PHONE: 434-422-9800
MAIL ADDRESS:
STREET 1: 1180 SEMINOLE TRAIL
STREET 2: SUITE 495
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22901
FORMER COMPANY:
FORMER CONFORMED NAME: ADial Pharmaceuticals, L.L.C.
DATE OF NAME CHANGE: 20170515
FORMER COMPANY:
FORMER CONFORMED NAME: Adial Pharmaceuticals, L.L.C.
DATE OF NAME CHANGE: 20110218
D
1
primary_doc.xml
X0708
D
LIVE
0001513525
ADIAL PHARMACEUTICALS, INC.
1180 SEMINOLE TRAIL
SUITE 495
CHARLOTTESVILLE
VA
VIRGINIA
22901
(434) 422-9800
DELAWARE
Adial Pharmaceuticals L.L.C.
ADial Pharmaceuticals, L.L.C.
Adial Pharmaceuticals, L.L.C.
Corporation
true
2017
William
B.
Stilley, III
1180 Seminole Trail, Suite 495
Charlottesville
VA
VIRGINIA
22902
Executive Officer
Director
Joseph
M.
Truluck
1180 Seminole Trail, Suite 495
Charlottesville
VA
VIRGINIA
22901
Executive Officer
James
K.
Anderson
1180 Seminole Trail, Suite 495
Charlottesville
VA
VIRGINIA
22901
Director
Robertson
H.
Gilliland
1180 Seminole Trail, Suite 495
Charlottesville
VA
VIRGINIA
22901
Director
James
W.
Newman, Jr.
1180 Seminole Trail, Suite 495
Charlottesville
VA
VIRGINIA
22901
Director
Kevin
Schuyler
1180 Seminole Trail, Suite 495
Charlottesville
VA
VIRGINIA
22901
Director
Tony
Goodman
1180 Seminole Trail, Suite 495
Charlottesville
VA
VIRGINIA
22901
Director
Pharmaceuticals
Decline to Disclose
- 06b
false
2021-03-11
false
true
false
0
2100003
291003
1809000
false
5
0
0
0
true
While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.
false
ADIAL PHARMACEUTICALS, INC.
/s/ William B. Stilley, III
William B. Stilley, III
Chief Executive Officer
2021-03-25